ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ancesol 10 mg/ml solution for injection for cattle
(AT, BE, BG, CZ, DE, EE, EL, ES, FI, IT, LT, LV, NL, PL, PT, RO, SI, SK)

Ancesol solution for injection for cattle
(FR)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substances:
Chlorphenamine maleate 10 mg
(equivalent to 7.03 mg chlorphenamine)

Excipients:

Qualitative composition of excipients and other constituents	**Quantitative composition if that information is essential for proper administration of the veterinary medicinal product**
Methyl parahydroxybenzoate (E218)	1.00 mg
Propyl parahydroxybenzoate	0.20 mg
Sodium dihydrogen phosphate dihydrate	
Sodium hydroxide (for pH adjustment)	
Water for injections	

Clear, colourless to almost colourless solution.

3. CLINICAL INFORMATION

3.1 Target species

Cattle.

3.2 Indications for use for each target species

For the symptomatic treatment of conditions associated with histamine release.

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Although intravenous administration has an immediate therapeutic effect, it can have excitatory effects on the CNS. Consequently, administer slowly and interrupt administration for a few minutes, if necessary, when using this route. Do not administer via the subcutaneous route.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Accidental self-injection may result in sedation. Care should be taken to avoid accidental self-injection with this drug. Preferably use a guarded needle until the moment of injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. DO NOT DRIVE.
Wash splashes from skin and eyes immediately.

Special precautions for the protection of the environment:
Not applicable.

3.6 Adverse events

Cattle:

Undetermined frequency (cannot be estimated from the available data):	Sedation[1]

[1] Weak.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit-risk assessment by the responsible veterinarian.

3.8 Interaction with other medicinal products and other forms of interaction

Concomitant use of other antihistamines or barbiturates may boost the sedative effect of chlorphenamine. The use of antihistamines may conceal early signs of ototoxicity caused by some antibiotics (e.g. aminoglycoside and macrolide antibiotics) and may shorten the effect of oral anticoagulants.

3.9 Administration routes and dosage

For intramuscular or intravenous use.
See also section “3.5 Special precautions for safe use in the target species”.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Adult animals:
0.5 mg Chlorphenamine maleate/kg bodyweight (5 ml/100 kg bodyweight), once a day for three consecutive days.

Calves:
1 mg Chlorphenamine maleate/kg bodyweight (10 ml/100 kg bodyweight), once a day for three consecutive days.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Doses up to four times the therapeutic dose have been well tolerated. In very rare cases, local reactions were observed in the neck region at the injection site. All the reactions were transient and resolved spontaneously.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

3.12 Withdrawal periods

Meat and offal: 1 day
Milk: 12 hours

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QR06AB04

4.2 Pharmacodynamics

Chlorphenamine maleate is a racemic compound classified as an alkyl amine group antihistamine that, due to its chemical characteristics, is able to bind to the H1 receptor present on the cell membrane and therefore compete with the natural endogenous ligand for the same site. Receptor occupation by chlorphenamine maleate does not, in itself, induce pharmacological responses, but significantly inhibits those induced by histamine. On the basis of these observations, chlorphenamine maleate behaves as a direct or reversible competitive receptor antagonist. Chlorphenamine maleate is not able to inhibit the synthesis or release of histamine.

4.3 Pharmacokinetics

After intravenous administration the plasma concentration of the active substance drops from 36 ng/ml to the method's limit of detection (1 ng/ml) 24 hours after administration. The elimination half-life ($T_{1/2\beta}$) is 2.11 hours, the mean residence time (MRT) is 2.35 hours, total clearance (Cl_B) 1.315 l/kg/h and the volume of distribution (V_d) just over 3 l/kg. Following intramuscular administration, peak concentration (C_{max} = 142 ng/ml) is reached in 28 minutes (T_{max}). Plasma concentrations then drop rapidly to reach values of 60 and 12 µg/kg after 2 and 8 hours before dropping below the limit of quantification (1 µg/kg) 24 hours after treatment. MRT and bioavailability were 3.58 hours and 100%, respectively.
The compound and its metabolites are excreted primarily via the kidneys in urine, with a small amount in unmodified form and the majority as a breakdown product, almost completely, within 24 hours.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

Shelf life after first opening the immediate packaging: 28 days

5.3 Special precautions for storage

After first opening do not store above 30 °C.

5.4 Nature and composition of immediate packaging

Amber glass vial, type II (Ph.Eur.) with bromobutyl-rubber stopper type I (Ph.Eur.) and aluminium cap in a cardboard box.

Pack sizes: 1 x 100 ml, 5 x 100 ml
Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

VetViva Richter GmbH

7. MARKETING AUTHORISATION NUMBER(S)

8. DATE OF FIRST AUTHORISATION

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard box 1 x 100 ml, 5 x 100 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ancesol 10 mg/ml solution for injection
(AT, BE, BG, CZ, DE, EE, EL, ES, FI, IT, LT, LV, NL, PL, PT, RO, SI, SK)

Ancesol solution for injection
(FR)

Chlorphenamine maleate

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:
Chlorphenamine maleate 10 mg
(equivalent to 7.03 mg chlorphenamine)

3. PACKAGE SIZE

1 x 100 ml
5 x 100 ml

4. TARGET SPECIES

Cattle

5. INDICATIONS

-

6. ROUTES OF ADMINISTRATION

For intramuscular or slow intravenous use..

7. WITHDRAWAL PERIODS

Withdrawal periods:
Meat and offal: 1 day
Milk: 12 hours

8. EXPIRY DATE

Exp. {mm/yyyy}
Once broached use within 28 days.

9. SPECIAL STORAGE PRECAUTIONS

After first opening do not store above 30 °C.

10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

11. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

VetViva Richter (logo)

14. MARKETING AUTHORISATION NUMBERS

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

100 ml amber glass vial, type II.

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ancesol 10 mg/ml solution for injection
(AT, BE, BG, CZ, DE, EE, EL, ES, FI, IT, LT, LV, NL, PL, PT, RO, SI, SK)

Ancesol solution for injection
(FR)

Chlorphenamine maleate

2. STATEMENT OF ACTIVE SUBSTANCES

Chlorphenamine maleate 10 mg/ml

3. TARGET SPECIES

Cattle

4. ROUTES OF ADMINISTRATION

For intramuscular or slow intravenous use.

Read the package leaflet before use.

5. WITHDRAWAL PERIODS

Withdrawal periods:
Meat and offal: 1 day
Milk: 12 hours

6. EXPIRY DATE

Exp. {mm/yyyy}
Once broached use within 28 days. Use by ....

7. SPECIAL STORAGE PRECAUTIONS

After first opening do not store above 30 °C.

8. NAME OF THE MARKETING AUTHORISATION HOLDER

VetViva Richter (logo)

9. BATCH NUMBER

Lot {number}

100 ml

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Ancesol 10 mg/ml solution for injection for cattle
(AT, BE, BG, CZ, DE, EE, EL, ES, FI, IT, LT, LV, NL, PL, PT, RO, SI, SK)

Ancesol solution for injection for cattle
(FR)

2. Composition

Each ml contains:

Active substances:

Chlorphenamine maleate (equivalent to 7.03 mg chlorphenamine)	10 mg

Excipients:

Methyl parahydroxybenzoate (E218)	1.00 mg
Propyl parahydroxybenzoate	0.20 mg

Clear, colourless to almost colourless solution.

3. Target species

Cattle

4. Indications for use

For the symptomatic treatment of conditions associated with histamine release.

5. Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special precautions for safe use in the target species:
Although intravenous administration has an immediate therapeutic effect, it can have excitatory effects on the CNS. Consequently, administer slowly and interrupt administration for a few minutes, if necessary, when using this route. Do not administer via the subcutaneous route.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Accidental self-injection may result in sedation. Care should be taken to avoid accidental self-injection with this drug. Preferably use a guarded needle until the moment of injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. DO NOT DRIVE.
Wash splashes from skin and eyes immediately.

Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:
Concomitant use of other antihistamines or barbiturates may boost the sedative effect of chlorphenamine. The use of antihistamines may conceal early signs of ototoxicity caused by some antibiotics (e.g. aminoglycoside and macrolide antibiotics) and may shorten the effect of oral anticoagulants.

Overdose:
Doses up to four times the therapeutic dose have been well tolerated. In very rare cases, local reactions were observed in the neck region at the injection site. All the reactions were transient and resolved spontaneously.

Special restrictions for use and special conditions for use:

Major incompatibilities:
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Cattle:

Undetermined frequency (cannot be estimated from the available data):

Sedation[1]

[1] Weak

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system:

8. Dosage for each species, routes and method of administration

For intramuscular or intravenous use.
To ensure a correct dosage, body weight should be determined as accurately as possible.

Adult animals:
0.5 mg Chlorphenamine maleate/kg bodyweight (5 ml/100 kg bodyweight), once a day for three consecutive days.

Calves:
1 mg Chlorphenamine maleate/kg bodyweight (10 ml/100 kg bodyweight), once a day for three consecutive days.

9. Advice on correct administration

See also section **"**Special precautions for safe use in the target species**"**.

10. Withdrawal periods

Meat and offal: 1 day
Milk: 12 hours

11. Special storage precautions

Keep out of the sight and reach of children.
Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after Exp. The expiry date refers to the last day of that month.
Shelf-life after first opening the immediate packaging: 28 days
After first opening do not store above 30 °C.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.
Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Pack sizes:
1 x 100 ml, 5 x 100 ml
Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse events:
VetViva Richter GmbH, Durisolstrasse 14, 4600 Wels, Austria

Local representatives and contact details to report suspected adverse events:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information